Contrasting Alvotech (NASDAQ:ALVO) and Celularity (NASDAQ:CELU)

Celularity (NASDAQ:CELU – Get Free Report) and Alvotech (NASDAQ:ALVO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

19.0% of Celularity shares are held by institutional investors. 52.9% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Celularity and Alvotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celularity -246.65% N/A -48.20%
Alvotech -50.62% N/A -11.71%

Risk and Volatility

Celularity has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Valuation and Earnings

This table compares Celularity and Alvotech”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celularity $26.55 million 0.59 -$91.72 million ($1.69) -0.29
Alvotech $588.90 million 2.33 $27.92 million ($0.82) -5.55

Alvotech has higher revenue and earnings than Celularity. Alvotech is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Celularity and Alvotech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity 1 0 0 0 1.00
Alvotech 2 0 5 0 2.43

Alvotech has a consensus target price of $8.40, indicating a potential upside of 84.62%. Given Alvotech’s stronger consensus rating and higher probable upside, analysts clearly believe Alvotech is more favorable than Celularity.

Summary

Alvotech beats Celularity on 9 of the 13 factors compared between the two stocks.

About Celularity

(Get Free Report)

Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

About Alvotech

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.